RSS-Feed abonnieren
DOI: 10.1055/a-1798-1829
Maternal Blood Angiogenic Factors and the Prediction of Critical Adverse Perinatal Outcomes Among Small-for-Gestational-Age Pregnancies
![](https://www.thieme-connect.de/media/ajp/202409/lookinside/thumbnails/10-1055-a-1798-1829_210183-1.jpg)
Abstract
Objective Our objective was to determine whether maternal blood angiogenic factors in suspected-small-for-gestational-age (sSGA) fetuses can predict critical adverse perinatal outcomes (CAPO) and improve risk assessment.
Methods Women with singleton pregnancies diagnosed with sSGA, between 24 and 356/7 weeks' gestation, were included. Clinical and sonographic comprehensive evaluations were performed at enrolment. Plasma angiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), were obtained at diagnosis. In parallel, three attending maternal-fetal-medicine specialists predicted the risk (1–5 scale) of these pregnancies to develop CAPO, based on the clinical presentation. CAPOs were defined as prolonged neonatal intensive care unit hospitalization, fetal or neonatal death, and major neonatal morbidity. Statistical analysis included sensitivity, specificity, positive and negative predictive values, and receiver-operating characteristic (ROC) curve analyses.
Results Of the 79 cases included, 32 were complicated by CAPO (40.5%). In SGA fetuses with CAPO, the sFlt-1/PlGF ratio was higher (p < 0.001) and PlGF was lower (p < 0.001) as compared with uncomplicated pregnancies. The areas under the ROC curves for specialists were 0.913, 0.824, and 0.811 and for PlGF and sFlt-1/PlGF ratio 0.926 and 0.900, respectively. CAPO was more common in pregnancies with absent end-diastolic flow or reversed end-diastolic flow (AEDF or REDF) in the umbilical artery upon enrolment (91.6%). Yet, 65.6% of cases involving CAPO occurred in patients without AEDF or REDF, and 66.6% of these cases were not identified by one or more of the experts. The sFlt-1/PlGF ratio identified 92.9% of the experts' errors in this group and 100% of the errors in cases with AEDF or REDF.
Conclusion Among sSGA pregnancies prior to 36 weeks' gestation, angiogenic factors testing can identify most cases later complicated with CAPO. Our data demonstrate for the first time that these markers can reduce clinician judgment errors. Incorporation of these measures into decision-making algorithms could potentially improve management, outcomes, and even health care costs.
Key Points
-
Angiogenic factors at diagnosis of sSGA can be used to predict CAPO.
-
The sFlt-1/PlGF ratio can flag sSGA pregnancies at increased risk.
-
The sFlt-1/PlGF ratio at admission of sSGA adds to clinical assessment.
Keywords
adverse perinatal outcomes - PLGF - SGA - sFlt-1/PlGF - angiogenic factors - clinical assessmentPublikationsverlauf
Eingereicht: 11. März 2021
Angenommen: 11. März 2022
Accepted Manuscript online:
15. März 2022
Artikel online veröffentlicht:
25. Mai 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Dollberg S, Haklai Z, Mimouni FB, Gorfein I, Gordon ES. Birth weight standards in the live-born population in Israel. Isr Med Assoc J 2005; 7 (05) 311-314
- 2 Militello M, Pappalardo EM, Ermito S, Dinatale A, Cavaliere A, Carrara S. Obstetric management of IUGR. J Prenat Med 2009; 3 (01) 6-9
- 3 Halliday HL. Neonatal management and long-term sequelae. Best Pract Res Clin Obstet Gynaecol 2009; 23 (06) 871-880
- 4 Barker DJ. The developmental origins of well-being. Philos Trans R Soc Lond B Biol Sci 2004; 359 (1449): 1359-1366
- 5 Carreno CA, Costantine MM, Holland MG, Ramin SM, Saade GR, Blackwell SC. Approximately one-third of medically indicated late preterm births are complicated by fetal growth restriction. Am J Obstet Gynecol 2011; 204 (03) 263.e1-263.e4
- 6 Lausman A, Kingdom J, Maternal F. et al; MATERNAL FETAL MEDICINE COMMITTEE. Intrauterine growth restriction: screening, diagnosis, and management. J Obstet Gynaecol Can 2013; 35 (08) 741-748
- 7 Lobmaier SM, Figueras F, Mercade I. et al. Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-for- gestational-age fetuses. Ultrasound Obstet Gynecol 2014; 43 (05) 533-540
- 8 Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365 (9461): 785-799
- 9 Maynard SE, Min JY, Merchan J. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111 (05) 649-658
- 10 Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen—a review. Placenta 2000; 21 (suppl A ): S16-S24
- 11 Nikuei P, Malekzadeh K, Rajaei M, Nejatizadeh A, Ghasemi N. The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia. Iran J Reprod Med 2015; 13 (05) 251-262
- 12 Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009; 24: 147-158
- 13 Tjoa ML, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van Wijk IJ. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98 (04) 600-607
- 14 Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188 (01) 177-182
- 15 Cowans NJ, Stamatopoulou A, Matwejew E, von Kaisenberg CS, Spencer K. First-trimester placental growth factor as a marker for hypertensive disorders and SGA. Prenat Diagn 2010; 30 (06) 565-570
- 16 Sibiude J, Guibourdenche J, Dionne MD. et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012; 7 (11) e50208
- 17 Vatten LJ, Åsvold BO, Eskild A. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction. Acta Obstet Gynecol Scand 2012; 91 (12) 1388-1394
- 18 Boutsikou T, Malamitsi-Puchner A, Economou E, Boutsikou M, Puchner KP, Hassiakos D. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev 2006; 82 (04) 235-239
- 19 Schlembach D, Wallner W, Sengenberger R. et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007; 29 (04) 407-413
- 20 Wallner W, Sengenberger R, Strick R. et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007; 112 (01) 51-57
- 21 Erez O, Romero R, Espinoza J. et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21 (05) 279-287
- 22 Verlohren S, Galindo A, Schlembach D. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202 (02) 161.e1-161.e11
- 23 Bednarek-Jędrzejek M, Kwiatkowski S, Ksel-Hryciów J. et al. The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes. J Perinat Med 2019; 47 (07) 732-740
- 24 Benton SJ, Hu Y, Xie F. et al. Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?. Am J Obstet Gynecol 2012; 206 (02) 163.e1-163.e7
- 25 Benton SJ, McCowan LM, Heazell AE. et al. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta 2016; 42: 1-8
- 26 Gomez-Roig MD, Mazarico E, Sabria J, Parra J, Oton L, Vela A. Use of placental growth factor and uterine artery doppler pulsatility index in pregnancies involving intrauterine fetal growth restriction or preeclampsia to predict perinatal outcomes. Gynecol Obstet Invest 2015; 80 (02) 99-105
- 27 Chaiworapongsa T, Romero R, Whitten AE. et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med 2016; 29 (08) 1214-1228
- 28 Chang YS, Chen CN, Jeng SF. et al. The sFlt-1/PlGF ratio as a predictor for poor pregnancy and neonatal outcomes. Pediatr Neonatol 2017; 58 (06) 529-533
- 29 American College of O, Gynecologists. ACOG Practice bulletin no. 134: fetal growth restriction. Obstet Gynecol 2013; 121 (05) 1122-1133
- 30 Subedi D, DeBoer MD, Scharf RJ. Developmental trajectories in children with prolonged NICU stays. Arch Dis Child 2017; 102 (01) 29-34
- 31 Verlohren S, Herraiz I, Lapaire O. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014; 63 (02) 346-352
- 32 Arduini D, Rizzo G. Normal values of pulsatility index from fetal vessels: a cross-sectional study on 1556 healthy fetuses. J Perinat Med 1990; 18 (03) 165-172
- 33 Baschat AA, Gembruch U. The cerebroplacental Doppler ratio revisited. Ultrasound Obstet Gynecol 2003; 21 (02) 124-127
- 34 Gómez O, Figueras F, Fernández S. et al. Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation. Ultrasound Obstet Gynecol 2008; 32 (02) 128-132
- 35 Illa M, Coloma JL, Eixarch E. et al. Growth deficit in term small-for-gestational fetuses with normal umbilical artery Doppler is associated with adverse outcome. J Perinat Med 2009; 37 (01) 48-52
- 36 Savchev S, Figueras F, Cruz-Martinez R, Illa M, Botet F, Gratacos E. Estimated weight centile as a predictor of perinatal outcome in small-for-gestational-age pregnancies with normal fetal and maternal Doppler indices. Ultrasound Obstet Gynecol 2012; 39 (03) 299-303
- 37 Figueras F, Oros D, Cruz-Martinez R. et al. Neurobehavior in term, small-for-gestational age infants with normal placental function. Pediatrics 2009; 124 (05) e934-e941
- 38 Eixarch E, Meler E, Iraola A. et al. Neurodevelopmental outcome in 2-year-old infants who were small-for-gestational age term fetuses with cerebral blood flow redistribution. Ultrasound Obstet Gynecol 2008; 32 (07) 894-899
- 39 Comas M, Crispi F, Cruz-Martinez R, Figueras F, Gratacos E. Tissue Doppler echocardiographic markers of cardiac dysfunction in small-for-gestational age fetuses. Am J Obstet Gynecol 2011; 205 (01) 57.e1-57.e6
- 40 Crispi F, Bijnens B, Figueras F. et al. Fetal growth restriction results in remodeled and less efficient hearts in children. Circulation 2010; 121 (22) 2427-2436
- 41 Crispi F, Figueras F, Cruz-Lemini M, Bartrons J, Bijnens B, Gratacos E. Cardiovascular programming in children born small for gestational age and relationship with prenatal signs of severity. Am J Obstet Gynecol 2012; 207 (02) 121.e1-121.e9
- 42 Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet 1989; 2 (8663): 577-580
- 43 Figueras F, Eixarch E, Gratacos E, Gardosi J. Predictiveness of antenatal umbilical artery Doppler for adverse pregnancy outcome in small-for-gestational-age babies according to customised birthweight centiles: population-based study. BJOG 2008; 115 (05) 590-594
- 44 Chan FY, Soong B, Lessing K. et al. Clinical value of real-time tertiary fetal ultrasound consultation by telemedicine: preliminary evaluation. Telemed J 2000; 6 (02) 237-242
- 45 Soto E, Romero R, Kusanovic JP. et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2012; 25 (05) 498-507
- 46 Duhig KE, Myers J, Seed PT. et al; PARROT trial group. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet 2019; 393 (10183): 1807-1818